To explore the impact of the PRG signature on clinical characteristics, we investigated the association between PRG signature and clinical factors in CRC patients, including age, gender, pathologic stage, TNM stage system, adjuvant chemotherapy, tumor location, MMR system, TP53 mutation status, KRAS mutation status, BRAF mutation status, and disease recurrence. This evidence concerns the gene TP53 and colorectal carcinoma.